Liver transplant and recurrent disease

Poordad, Fred

doi:10.1016/j.cld.2004.02.011

Cited by 4 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to note that many of the HCC+/HCV‐ patients were HBV positive (42.1%, Table ). The comparable survival is probably as a result of the fact that transplantation is curative in HBV‐positive recipients and graft re‐infection is now a rarity since the introduction of hepatitis B immune globulin and nucleoside analogue prophylaxis …”

Section: Discussionmentioning

confidence: 99%

“…The comparable survival is probably as a result of the fact that transplantation is curative in HBV-positive recipients and graft re-infection is now a rarity since the introduction of hepatitis B immune globulin and nucleoside analogue prophylaxis. 25,34 It is noteworthy that the underlying cause of ESLD in HCC differs between regions. 4,35 While HCV is the leading cause of cirrhosis in Europe, North America and Japan, HBV is the main cause of ESLD in Africa and Asia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20‐year experience

Dumitra

Alabbad

Barkun

et al. 2013

HPB

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20‐year experience

Dumitra

Alabbad

Barkun

et al. 2013

HPB

View full text Add to dashboard Cite

show abstract

“…Indeed, the recognition of the adverse effect of older donor age on the post‐LTx course of HCV(+) recipients may have already changed clinical practice, as the proportion of HCV(+) recipients receiving a high‐DRI graft in our analysis was lower than that of HCV(−) recipients [8% of HCV(+) recipients received a graft with DRI ≥ 2, whereas 10.4% of HCV(−) recipients received a graft with DRI ≥ 2; data not shown]. Interestingly, older donor age has not been shown to predict adverse outcome in patients transplanted for chronic hepatitis B,23 presumably because graft reinfection with hepatitis B virus is now rare since the introduction of hepatitis B immune globulin and nucleoside analogue prophylaxis 27…”

Section: Discussionmentioning

confidence: 99%

Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients

Maluf¹,

Edwards²,

Stravitz³

et al. 2009

Liver Transpl

View full text Add to dashboard Cite

We have investigated the impact of the donor risk index (DRI) on the outcome of hepatitis C virus (HCV)-infected patients undergoing liver transplantation (LTx). Retrospective analysis was performed from the Organ Procurement and Transplantation Network database (January 1, 2000 to June, 2006). The DRI was calculated as described by Feng et al. (Am J Transplant 2006;6:783-790). Model for End-Stage Liver Disease (MELD) exceptions were excluded from the analysis. Relative risk (RR) estimates of patient and graft loss were derived from Cox regression models. The Wald test was used to test the effect of the MELD score at transplant on the HCV-DRI interaction. Of the LTx recipients (16,678), 76.1% were Caucasian, and 66.7% were male; the median age was 52 (range, 18-80 years), and the mean follow-up time was 1148 days (range, 0-2959 days). Forty-six percent (n ϭ 7675) of LTx recipients were HCV(ϩ). The median DRI was 1.3 (range, 0.77-4.27). Increasing DRI was associated with a statistically significant increase in the RR of graft failure and patient death for both HCV(ϩ) and HCV(Ϫ) recipients. However, HCV(ϩ) recipients demonstrated a significantly higher increase in the RR of patient and graft loss as a function of the DRI than HCV(Ϫ) subjects, even after adjustments for several recipient factors, including MELD. In conclusion, a synergistic interaction between donor DRI and recipient HCV status exists, such that an allograft from a high-DRI donor more adversely affects the outcome of an HCV(ϩ) recipient than that of an HCV(Ϫ) recipient. Liver Transpl 15:592-599, 2009.

show abstract

“…Recurrence of hepatitis B infection after liver transplantation is universal unless active prophylaxis with a combination of an antiviral and hepatitis B immunoglobulin is taken. 12 The risk of recurrence is greatest in patients with high HBV DNA prior to liver transplantation. It can be reduced with the use of lamivudine or adefovir before liver transplantation.…”

Section: Resultsmentioning

confidence: 99%

Spectrum of Complications in Post Liver Transplant Patients: A Study of 30 Cases

Siddiqui¹,

Jabeen

Ansari³

et al. 2008

j liaquat uni med health sci

View full text Add to dashboard Cite

Liver transplant and recurrent disease

Cited by 4 publications

References 54 publications

Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20‐year experience

Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20‐year experience

Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients

Spectrum of Complications in Post Liver Transplant Patients: A Study of 30 Cases

Contact Info

Product

Resources

About